Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer

By LabMedica International staff writers
Posted on 07 Apr 2026

Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. More...

Only a subset of patients benefit from immune checkpoint inhibitors, and existing markers such as PD-L1 are limited by technical complexity and inconsistent assessment. Standard immunohistochemistry is available in most pathology laboratories. Researchers now present a tumor-cell biomarker that stratifies response to neoadjuvant immunotherapy before surgery.

At Zhejiang Cancer Hospital, in collaboration with Peking University, investigators identified tumor-specific major histocompatibility complex class II (tsMHC-II) expression in cancer cells as a predictive biomarker for response to neoadjuvant immunotherapy in locally advanced gastric cancer. The findings, published in Science Bulletin, indicate that tsMHC-II can be evaluated with routine immunohistochemistry and interpreted more consistently than PD-L1. The approach is designed to support pre-surgical treatment selection.

Using comprehensive single-cell RNA sequencing of tumor samples from patients receiving neoadjuvant immunotherapy, the team observed that tsMHC-II expression correlated with treatment sensitivity. Mechanistic analyses indicated that interferon-gamma signaling upregulates MHC-II in tumor cells, enhancing immune recognition and therapeutic responsiveness. In the discovery work, patients underwent neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors.

Across the analyzed cohort, tsMHC-II-positive tumors were associated with higher pathological complete response (pCR) and major pathological response (MPR) rates than tsMHC-II-negative tumors. Patients with tsMHC-II-positive disease achieved a pCR rate of 36.84% versus 11.11% in tsMHC-II-negative disease, and an MPR rate of 63.16% versus 25.93%. These differences align with the observed linkage between tumor-intrinsic antigen presentation and treatment sensitivity.

To validate the biomarker prospectively, the researchers conducted a clinical trial enrolling 30 patients selected for tsMHC-II-positive tumors. In this cohort, 36.67% achieved pCR and 66.67% achieved MPR, results described as significantly higher than typically observed in unselected populations. The authors note that tsMHC-II assessment offers clear and consistent readouts using standard pathology methods.

The study appears in Science Bulletin. According to the institutions, the discovery provides a practical predictive tool and mechanistic insight for refining neoadjuvant immunotherapy strategies in gastric cancer, and larger multi-center trials are planned.

"This biomarker could transform how we select patients for neoadjuvant immunotherapy," Professor Xiangdong Cheng said, one of the study's corresponding authors. "By identifying patients most likely to benefit, we can improve outcomes while sparing non-responders from unnecessary treatments and side effects."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.